Skip to main content
Equibles
ZVRA logo

ZVRA · Zevra Therapeutics, Inc.

Track ZVRA — free

Use ZVRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.30 -0.24 (-1.91%)
Russell 2000 member Rebalance outlook locked
Market Cap
$732.80M
Shares
59.38M

ZVRA metrics

72 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.54
Market cap
$732.80M

Price action

19 metrics
Price change (1W)
+5.8%
Price change (30D)
+19.1%
Price change (3M)
+12.3%
Price change (6M)
+42.7%
Price change (YTD)
+40.0%
Price change (1Y)
+40.6%
Trailing year
Price change (5Y)
+30.8%
52-week high
$14.75
52-week low
$7.23
Change from 52-week high
-15.0%
Change from 52-week low
+73.4%
Annualized volatility
63.4%
Beta
0.8
RSI (14D)
60.7
Price vs SMA 50
+4.0%
Price vs SMA 200
+22.1%
Avg volume (3M)
1.46M
Relative volume
0.6
Average dollar volume
$17.75M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
59.38M

Valuation

12 metrics
P / E (TTM)
13.3
Trailing earnings · reciprocal yield 7.5%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.4×
reciprocal yield 18.6%
P / book
3.4
reciprocal yield 29.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
21.9
reciprocal yield 4.6%
Earnings yield
8.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.5×
reciprocal yield 15.3%
EV / revenue historical average (5Y)
8.5×
reciprocal yield 11.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
60.5%
Trailing 12 months
Net margin
42.8%
Gross profit (TTM)
—
Operating profit (TTM)
$82.38M
Net income (TTM)
$58.26M
Trailing 12 months
Diluted EPS (TTM)
$0.94
FCF margin
—
Effective tax rate
15.9%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-325.96

Growth

11 metrics
Revenue growth YoY
+53.3%
Year over year
Net income growth YoY
-88.3%
Revenue (TTM)
$136.07M
Trailing 12 months
EPS growth YoY
-88.4%
Shares change YoY
+8.9%
Year over year · more shares
Revenue CAGR (3Y)
+118.8%
Revenue CAGR (5Y)
+51.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
26.8%
Return on assets
19.2%
Debt / equity
0.0
Current ratio
5.2
EBITDA (TTM)
$83.87M
Free cash flow (TTM)
—
Quick ratio
5.1
Interest coverage
14.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$145.32M
Total assets
$302.71M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$33.40M
Capital expenditures (TTM)
—
R&D (TTM)
$14.93M
SG&A (TTM)
$74.63M
Stock compensation (TTM)
$13.13M
R&D / revenue
11.0%
Stock compensation / revenue
9.6%

Ownership (13F)

3 metrics
13F filers
157
13F filer change QoQ
+8
Institutional ownership
80.8%

Short interest

3 metrics
Short interest
10.9%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.05M
Insider-sentiment score
47 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1434647 CUSIP 488445206 13F (30d) 124 filings 122 filers Visit website Investor relations